View live charts, options flow & technicals for Zoetis Inc. →
Open Dashboard
Zoetis Inc. (ZTS) is a healthcare company in the drug manufacturers - specialty & generic industry with $9.53B in trailing revenue trading at a 11.9× trailing P/E — analyst consensus: none.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Key Statistics
Market Cap
$29.59B
Revenue (TTM)
$9.53B
EPS (TTM)
$6.02
EPS (Fwd est.)
$6.53
Employees
14,500
Trailing P/E
11.90
Forward P/E
10.96
PEG Ratio
6.78
Price / Sales
3.11
EV / EBITDA
9.14
Beta (5Y)
0.73
Analyst Consensus
Consensus
None
Analyst Price Target
+34.1% upside
Target: $96.00
Annual Revenue & Net Income
RevenueNet Income
'22
$8.08B
$2.11B
'23
$8.54B
$2.34B
'24
$9.26B
$2.49B
'25
$9.47B
$2.67B
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$1.87
$1.85
Beat (+0.9%)
May 2026
$1.53
$1.62
Miss (-5.3%)
Feb 2026
$1.48
$1.40
Beat (+5.5%)
Nov 2025
$1.70
$1.62
Beat (+4.8%)
Next Earnings Report
Zoetis Inc. is next expected to report earnings on 03 Nov 2026.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species,…
What is ZTS's market cap?
Zoetis Inc. has a market capitalization of approximately $29.59B.
What is ZTS's P/E ratio?
Zoetis Inc. trades at a trailing P/E ratio of 11.9x and a forward P/E of 11.0x, which is below the broad market average of ~25x.
How much revenue does ZTS generate?
Zoetis Inc. generated $9.53B in trailing 12-month revenue.
What do analysts say about ZTS?
The analyst consensus rating for Zoetis Inc. is none, with a mean price target of $96.00. That implies +34.1% upside from the current price.
When does ZTS report earnings?
Zoetis Inc. is next scheduled to report earnings on 03 Nov 2026.
Does ZTS pay a dividend?
Yes. Zoetis Inc. pays a dividend with a current yield of 2.91%, at an annual rate of $2.12 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Zoetis Inc. on Apsis Markets.
